We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Valirx plc (VAL) ORD GBP0.001

Sell:0.70p Buy:0.75p 0 Change: No change
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.70p
Buy:0.75p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.70p
Buy:0.75p
Change: No change
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

Contact details

Address:
Eliot Park Innovation Centre
4 Barling Way
NUNEATON
CV10 7RH
United Kingdom
Telephone:
+44 (024) 76796496
Website:
https://www.valirx.com/

Important dates

Future events
General meeting 30 December 2024 30/12/24
Past events
Interim results 27 September 2024 27/09/24
AGM 20 June 2024 20/06/24
Final results 15 May 2024 15/05/24
General meeting 04 January 2024 04/01/24

General stock information

EPIC:
VAL
ISIN:
GB00BLH13C52
Market cap:
£959,528
Shares in issue:
132.35 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Mark Eccleston
    Chief Executive Officer, Director
  • Gerald Desler
    Chief Financial Officer, Executive Director, Company Secretary
  • Catherine Tralau-Stewart
    Chief Scientific Officer, Executive Director
  • Zai Ahmad
    Pre-clinical Project Manager
  • Andrew Carnegie
    Head of Strategic Commercial Development
  • Kumar Nawani
    Head of Operations
  • Mark Treharne
    Corporate Development Manager

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.